KW-8232 free base

Modify Date: 2024-01-10 15:16:39

KW-8232 free base structure	Common Name	KW-8232 free base
	CAS Number	170365-25-0	Molecular Weight	609.16
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₆H₃₇ClN₄O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of KW-8232 free base

KW-8232 free base is an anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.

Name	KW-8232 free base

Description	KW-8232 free base is an anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor Research Areas >> Metabolic Disease
Target	Prostaglandin Receptor[1]
In Vitro	KW-8232 free base is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1].
In Vivo	KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1].
Animal Admin	After male Sprague-Dawley rats (5-week-old) are anesthetized with sodium pentobarbital (30 mg/kg, i.p.), a dorsolateral incision is made on the right hip through which the sciatic nerve is exposed, and a 0.5-cm section is excised. The contralateral leg is left intact. KW-8232 is dissolved in distilled water and administered orally at 1, 3, 10, and 30 mg/kg once daily beginning 1 day prior to neurectomy. On day 28, rats are exsanguinated under diethyl ether agter obtaining urine, and their femurs are removed. Bone mineral density (BMD) is determined by dual energy x-ray absorptiometry. Twenty-four hour urine samples are collected from the animals, which are fasted immediately after the final administration of KW-8232[1].
References	[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3.

Molecular Formula	C₃₆H₃₇ClN₄O₃
Molecular Weight	609.16